Key facts
- Scopio Labs’s last known valuation is $85.3M (Jul 2025).
- It has raised $154.1M.
- Notable investors include European Commission, OurCrowd, GlenRock Israel, Insight Capital Partners, Arbelon Holdings — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Scopio Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Scopio Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Scopio Labs
Developer of a computational microscope and diagnostics equipment designed for easy and wide access to microscopy and diagnostics. The company's equipment offers a suite of fully digital diagnostic applications and imaging platforms that enhance clinical workflows with proper detection and diagnosis of blood-related diseases, enabling hematology labs to assess and analyze cell morphology at depth, making the diagnosis process more efficient and consistent across the continuum of care.
- Sector
- Healthcare
- HQ
- Tel Aviv, Israel
- Founded
- 2014
- Employees
- 157
- Website
- scopiolabs.com/
- Ownership
- Privately Held (backing)
Scopio Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Scopio Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Scopio Labs in its N-PORT filings yet. We sweep new filings monthly.